On June 22, 2022 Biogen (NASDAQ:BIIB) and Happify Health (www.HappifyHealth.com), the Intelligent Healing Company, reported a collaboration to provide a digital solution for patient education and engagement, powered by artificial intelligence (AI), to support people living with multiple sclerosis (MS) (Press release, Biogen, JUN 22, 2022, View Source [SID1234616185]). Through this collaboration, Biogen and Happify Health will help people with MS manage their care journey, improve their wellbeing, learn about treatment options, consult with experts, and connect with other people in the MS community for support.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

More than 2.3 million people live with MS globally, including over 1 million people in the United States, according to the National MS Society. Women are two to three times more likely to develop MS than men1.

"This collaboration is one of many ways we are focused on supporting patients by meeting them where they are. The combination of Biogen’s expertise in neuroscience and our commitment to digital health, along with Happify Health’s AI and digital therapeutic capabilities will help drive a connected and comprehensive experience that allows patients to feel supported throughout their journey," said Jason Hawbecker, Head of Strategic Partnerships & Collaborations at Biogen. "We are excited about the potential of this partnership to provide overall support for the MS community."

The Happify Health solution, which brings together a digital tool configured for MS and a care community (Kopa), offers holistic health and wellness support, with access to neurology providers (doctors, nurse practitioners, physicians assistants and nurses) as well as mental health specialists, dietitians, and rehabilitation professionals. The online community that recently launched provides a place for those living with MS to ask experts questions and discuss the physical and mental challenges they are facing with patients in similar stages. Happify Health uses its proprietary AI technology to personalize content to patients’ life stages, symptoms and interests.

"It can be challenging for people living with MS to stay up-to-date with the latest treatments, interpret new symptoms, or investigate changes in their health that may or may not be related to MS," said Ofer Leidner, President of Happify Health. "We are providing the MS community with a solution configured to accommodate their specific needs, as well as opportunities to engage with experts, receive curated content, and discuss disease management with other community members. We are very excited to partner with Biogen on this opportunity given their leadership in the MS space."

Biogen, a global leader in developing treatments for people living with serious neurological and neurodegenerative diseases, will provide support for the MS platform, including educational content and resources for the patient care journey. The company is a global leader in treating MS with a portfolio of medicines to treat relapsing forms of MS, characterized by periods where symptoms subside, with full or partial recovery, and there is no disease progression between attacks.

In addition to psoriasis and maternal health, MS is the third therapeutic area to be addressed through Happify Health’s unique SequenceTM approach. Sequences are configured to support specific medical conditions and weave together components like evidence-based digital therapeutics, online communities, and coaching in one unified platform, with recommendations tailored for each individual.

On June 22, 2022, bluebird bio, Inc. (the "Company") reported that entered into an Equity Distribution Agreement (the "Equity Distribution Agreement") with Goldman Sachs & Co. LLC ("Goldman") to sell shares of the Company’s common stock, par value $0.01 per share (the "Common Stock"), with aggregate gross sales proceeds of up to $75.0 million, from time to time, through an "at the market" equity offering program under which Goldman will act as manager (Filing, 8-K, bluebird bio, JUN 22, 2022, View Source [SID1234616170]). The Equity Distribution Agreement also provides for the sale of shares to Goldman directly as principal, in which case the Company and Goldman will enter into a separate terms agreement ("Terms Agreement").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the Equity Distribution Agreement, the Company will set the parameters for the sale of shares, including any price, time or size limits or other customary parameters or conditions. The Company intends to sell shares pursuant to the Equity Distribution Agreement from time to time in varying amounts, which may be limited, based upon factors including (among others) market conditions, trading liquidity, the trading price of the Company’s Common Stock, and determinations by the Company of its need for, and appropriate sources of, additional capital. Subject to the terms and conditions of the Equity Distribution Agreement, Goldman may sell the shares by any method permitted by law, including without limitation (i) by means of ordinary brokers’ transactions (whether or not solicited), (ii) to or through a market maker, (iii) directly on or through any national securities exchange or facility thereof, a trading facility of a national securities association, an alternative trading system, or any other market venue, (iv) in the over-the-counter market, (v) in privately negotiated transactions, or (vi) through a combination of any such methods. The Company will pay Goldman a commission equal to up to 3.0% of the gross proceeds of any Common Stock sold through Goldman under the Equity Distribution Agreement, and also has provided Goldman with customary representations, warranties, covenants and indemnification rights. The Equity Distribution Agreement may be terminated by the Company upon written notice to Goldman or by Goldman upon written notice to the Company. In the case of any purchase of shares by Goldman directly as principal pursuant to a Terms Agreement, such Terms Agreement may be terminated by Goldman upon notice to the Company under certain circumstances, including but not limited to the occurrence of a material adverse effect in the Company.

Any sales of shares under the Equity Distribution Agreement will be made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-236489) filed with the Securities and Exchange Commission (the "Commission") on February 18, 2020, which was automatically effective upon filing. The Company filed a prospectus supplement with the Commission on June 22, 2022 in connection with the offer and sale of the shares pursuant to the Equity Distribution Agreement.

The foregoing is only a brief description of the material terms of the Equity Distribution Agreement and is qualified in its entirety by reference to the full agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Latham & Watkins LLP, counsel to the Company, has issued an opinion to the Company, dated June 22, 2022, regarding the validity of the shares of Common Stock to be issued and sold pursuant to the Equity Distribution Agreement. A copy of the opinion is filed as Exhibit 5.1 to this Current Report on Form 8-K.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of any offer to buy the securities discussed herein, nor shall there be any offer, solicitation or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

On June 22, 2022 Daiichi Sankyo (TSE: 4568) reported that the European Medicines Agency (EMA) has validated the Type II Variation application for trastuzumab deruxtecan as monotherapy for the treatment of adult patients with unresectable or metastatic HER2 low (immunohistochemistry (IHC) 1+ or IHC 2+/in-situ hybridization (ISH)-negative) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy (Press release, Daiichi Sankyo, JUN 22, 2022, View Source [SID1234616186]). Patients with hormone receptor (HR) positive breast cancer must additionally have received or be ineligible for endocrine therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Trastuzumab deruxtecan is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN).

Validation confirms that the application is complete and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). This application is based on data from the DESTINY-Breast04 phase 3 trial recently presented at the plenary session of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) (#ASCO22) Annual Meeting and simultaneously published in The New England Journal of Medicine.

"Trastuzumab deruxtecan is the first HER2 directed therapy to demonstrate a survival benefit in patients with HER2 low metastatic breast cancer. We now have the potential to redefine how we classify and treat approximately half of all metastatic breast cancers," said Gilles Gallant, BPharm, PhD, FOPQ, Senior Vice President, Global Head, Oncology Clinical Development, Oncology R&D, Daiichi Sankyo. "In addition to the ongoing review of two other applications for the treatment of patients with HER2 positive metastatic breast cancer or gastric cancer in Europe, we are pleased to have received this third validation for HER2 low metastatic breast cancer with the goal of bringing trastuzumab deruxtecan to as many eligible patients with HER2 targetable cancers as possible."

In DESTINY-Breast04, trastuzumab deruxtecan demonstrated superior and clinically meaningful efficacy in progression-free survival (PFS) and overall survival (OS) in previously treated patients with HER2 low unresectable and/or metastatic breast cancer with HR positive or HR negative disease versus standard of care physician’s choice of chemotherapy. The safety profile of trastuzumab deruxtecan was consistent with previous clinical trials with no new safety concerns identified. Interstitial lung disease (ILD) or pneumonitis rates were consistent with that observed in late-line HER2 positive breast cancer trials of trastuzumab deruxtecan with a lower rate of grade 5 ILD observed, as determined by an independent adjudication committee.

About DESTINY-Breast04

DESTINY-Breast04 is a global, randomized, open-label, pivotal phase 3 trial evaluating the efficacy and safety of trastuzumab deruxtecan (5.4 mg/kg) versus physician’s choice of chemotherapy (capecitabine, eribulin, gemcitabine, paclitaxel or nab-paclitaxel) in patients with HR positive or HR negative, unresectable and/or metastatic breast cancer with low HER2 expression previously treated with one or two prior lines of chemotherapy. Patients were randomized 2:1 to receive either trastuzumab deruxtecan or chemotherapy.

The primary endpoint of DESTINY-Breast04 is PFS in patients with HR positive disease based on blinded independent central review (BICR). Key secondary endpoints include PFS based on BICR in all randomized patients (HR positive and HR negative disease), OS in patients with HR positive disease and OS in all randomized patients (HR positive and HR negative disease). Other secondary endpoints include PFS based on investigator assessment, objective response rate based on BICR and on investigator assessment, duration of response based on BICR and safety. DESTINY-Breast04 enrolled 557 patients at multiple sites in Asia, Europe and North America. For more information about the trial, visit ClinicalTrials.gov.

About Breast Cancer and HER2 Expression

Breast cancer is the most common cancer and is one of the leading causes of cancer-related deaths worldwide.1 More than two million cases of breast cancer were diagnosed in 2020 resulting in nearly 685,000 deaths globally.1 In Europe, approximately 531,000 cases of breast cancer are diagnosed annually.2

HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumors including breast, gastric, lung and colorectal cancers, and is one of many biomarkers expressed in breast cancer tumors.3

HER2 expression is currently defined as either positive or negative, and is determined by an IHC test which estimates the amount of HER2 protein on a cancer cell, and/or an ISH test, which counts the copies of the HER2 gene in cancer cells.3,4 HER2 positive cancers are defined as IHC 3+, IHC 2+/ISH+.3 HER2 negative cancers are currently defined as IHC 0, IHC 1+ or IHC 2+/ISH-.3 Approximately half of all patients with breast cancer have tumors with a HER2 IHC score of 1+, or a HER2 IHC score of 2+ in combination with a negative ISH test, an expression level not currently eligible for HER2 targeted therapy.5,6,7,8 Low HER2 expression occurs in both HR positive and HR negative disease.9

HER2 testing is routinely used to determine appropriate treatment options for patients with metastatic breast cancer. Targeting the lower range of expression in the HER2 spectrum may offer another approach to delay disease progression and extend survival in patients with metastatic breast cancer.10 Currently, patients with low HER2 expression with HR positive tumors have limited treatment options following progression on endocrine (hormone) therapy.11 Few targeted options are available for those who are HR negative.12

About Trastuzumab Deruxtecan

Trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki in the U.S. only) is a HER2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, trastuzumab deruxtecan is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca’s ADC scientific platform. Trastuzumab deruxtecan consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker.

Trastuzumab deruxtecan (5.4 mg/kg) is approved in Canada, Israel and the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy, based on results from the DESTINY-Breast03 trial. Trastuzumab deruxtecan also is approved in approximately 40 countries for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2-based regimens based on the results from the DESTINY-Breast01 trial.

Trastuzumab deruxtecan (6.4 mg/kg) is approved in several countries for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial.

About the Trastuzumab Deruxtecan Clinical Development Program

A comprehensive global development program is underway evaluating the efficacy and safety of trastuzumab deruxtecan monotherapy across multiple HER2 targetable cancers including breast, gastric, lung and colorectal cancers. Trials in combination with other anticancer treatments, such as immunotherapy, also are underway.

Regulatory applications for trastuzumab deruxtecan are currently under review in China, Europe, Japan and several other countries for the treatment of adult patients with HER2 positive unresectable or metastatic breast cancer who have received a prior anti-HER2-based regimen based on the results from the DESTINY-Breast03 trial.

Trastuzumab deruxtecan also is currently under review in the U.S. for the treatment of adult patients with unresectable or metastatic NSCLC whose tumors have a HER2 (ERBB2) mutation and who have received a prior systemic therapy based on the results from the DESTINY-Lung01 trial, and in Europe for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or GEJ adenocarcinoma who have received a prior anti-HER2-based regimen based on the DESTINY-Gastric01 and DESTINY-Gastric02 trials.

Trastuzumab deruxtecan was granted Breakthrough Therapy Designation in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy based on the results of the DESTINY-Breast04 trial. Patients with HR positive breast cancer should additionally have received or be ineligible for endocrine therapy.

About the Daiichi Sankyo and AstraZeneca Collaboration

Daiichi Sankyo Company, Limited (referred to as Daiichi Sankyo) and AstraZeneca entered into a global collaboration to jointly develop and commercialize trastuzumab deruxtecan in March 2019 and datopotamab deruxtecan (Dato-DXd) in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of trastuzumab deruxtecan and datopotamab deruxtecan.

On June 22, 2022 National Brain Tumor Society reported that the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new treatment combination that will now be available as an option for certain brain tumor patients (Press release, National Brain Tumor Society, JUN 22, 2022, View Source [SID1234616328]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The FDA approved the combination of two oral drugs called dabrafenib (brand name: Tafinlar) and trametinib (brand name: Mekinist) for the treatment of advanced tumors that have a mutation called "BRAF V600E." The approval includes use in both adult and pediatric (older than 6 years of age) high- and low-grade glioma patients with this mutation whose tumors progressed after prior treatment.

The approval is based on the results from a number of clinical trials, which included adult and pediatric high-grade and low-grade glioma patients. Data pooled from across these trials showed that the Tafinlar-Mekinist combination successfully shrank a significant percentage of these patients’ tumors. Using a measure called "Overall Response Rate (ORR)," trials found that 33% of high-grade glioma patients responded to the combination, while 50% of low-grade glioma patients saw tumor shrinkage benefits. For the pediatric glioma patients, 25% responded to the treatment.

The BRAF V600E mutation is estimated to be prevalent in 5-15% of all low-grade gliomas (15-20% of pediatric low-grade gliomas), including 60-80% of pleomorphic xanthoastrocytomas (PXA), 20-70% of gangliogliomas, and 10% of pilocytic astrocytomas. The mutation has been identified less frequently in high-grade gliomas, including approximately 3% of glioblastomas.

"This approval will offer a much-needed new treatment option for hundreds of glioma patients with a BRAF V600E mutation," said David Arons, chief executive officer, National Brain Tumor Society. "This is very positive news for the brain tumor community and offers hope that current research and drug development efforts are beginning to yield meaningful breakthroughs for patients that currently have too few options. We thank Novartis for including both adult and pediatric glioma patients in these trials, as well as the researchers and clinicians involved, and most importantly the patients and their families that participated in the studies."

The most common side effects seen in adult patients were fever, fatigue, nausea, rash, chills, headache, hemorrhage, cough, vomiting, constipation, diarrhea, muscle and joint pain, and edema.

The most common side effects seen in pediatric patients included fever, rash, vomiting, fatigue, dry skin, cough, diarrhea, dermatitis acneiform, headache, abdominal pain, nausea, hemorrhage, and constipation.

Because the approval for this treatment was granted through the FDA’s accelerated approval pathway, the sponsor of the clinical trial, Novartis, will be required to complete confirmatory trials to verify the effectiveness of these drugs to date. According to reports, the company may already have additional evidence of effectiveness in pediatric low-grade glioma patients, including in children as young as one. Based on data presented recently at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting, the Tafinlar-Mekinist combination resulted in 47% ORR versus chemotherapy (11%) and reduced the risk of progression or death by 69%. Additionally, in a separate, small subset of this trial, pediatric high-grade glioma patients treated with Tafinlar-Mekinist showed an ORR of 56.1% and generally consistent safety results.

Further buoying these results were data also presented at ASCO (Free ASCO Whitepaper) 2022 from Day One Bio of their own BRAF-targeting drug, tovorafenib (DAY101), which also showed effectiveness in relapsed pediatric low-grade glioma. We await additional future results from trials of tovorafenib (DAY101).

"Given this latest approval, and the recent data from ASCO (Free ASCO Whitepaper), NBTS strongly urges that neuro-surgical and oncology providers treating glioma patients secure for patients a test that can identify their BRAF V600E status as part of robust molecular biomarker testing informed by the 2021 World Health Organization’s reclassification of CNS tumors as a routine step that could determine which patients could benefit from these drugs," added Arons.

On June 22, 2022 The Cancer Research Institute (CRI), a nonprofit organization dedicated to the discovery and development of powerful immunotherapies for all types of cancer, reported the newest cohort of scientists chosen for the CRI Lloyd J. Old STAR Program (Scientists Taking Risks) (Press release, Cancer Research Institute, JUN 22, 2022, View Source [SID1234616171]). Each STAR will receive a grant of $1.25 million payable over five years to carry out high-risk/high-reward research that has the potential to produce transformative leaps forward in tumor immunology. This long-term funding provides a degree of flexibility and freedom for CRI STARs to explore new and disruptive avenues of cancer research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The competitive CRI Lloyd J. Old STAR program supports gifted, mid-career scientists working at the intersection of immunology, technology, and bioinformatics to identify specific molecular and genetic factors that influence patient responses to immunotherapy, discovering answers to the field’s key scientific questions to potentially effect a sea change in how cancer patients are diagnosed and treated," said Jill O’Donnell-Tormey, Ph.D., CEO and director of scientific affairs at the Cancer Research Institute, which now actively supports twenty-two STARs throughout the U.S. and Europe.

The announcement comes during the tenth annual Cancer Immunotherapy Month celebrations in June of scientists who are driving new and lifesaving advances in the immunological treatment and prevention of cancer. This year’s Cancer Research Institute Lloyd J. Old STARs include:

Iliyan D. Iliev, Ph.D., of Weill Cornell Medicine, who is breaking new ground in efforts to understand the role fungi play in cancer development and immunotherapy, characterizing how different fungal strains promote or inhibit cancer growth through interaction of their metabolites and toxins with the immune system, and determining how the presence of fungi within the tumor microenvironment and blood influences – and may even predict – patient responses to treatment with immunotherapy
Philip J. Kranzusch, Ph.D., of the Dana-Farber Cancer Institute and Harvard Medical School, who has discovered and is exploring thousands of previously uncharacterized signaling enzymes from the cGAS family involved in immune cell responses to threats, using biochemistry and structural biology to uncover the functions of these enzymes and their related cellular pathways in order to define at the molecular level how they are activated, potentially leading to new, more effective therapeutic strategies
Kole T. Roybal, Ph.D., of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center and Gladstone-UCSF Institute of Genomic Immunology, who has developed a synthetic biology approach to modifying immune cell receptor and signaling gene programs to create "smart cell" therapeutics with enhanced abilities to target tumors more precisely and more safely than current cell therapies, which have so far proven largely ineffective against solid tumors despite their successes in treating cancers of the blood
Brian Ruffell, Ph.D., of the H. Lee Moffitt Cancer Center and Research Institute, who aims to improve patient responses to immunotherapy by using CRISPR-Cas9 genetic screens to define specific molecular pathways involved in suppression of dendritic cells – key orchestrators of the immune response to cancer and other threats – in order to identify and validate targets of immunotherapy for preclinical development
Ansuman T. Satpathy, M.D., Ph.D., of Stanford University School of Medicine, Stanford Cancer Institute, and Gladstone-UCSF Institute of Genomic Immunology, who is using new genetic analysis technologies capable of scanning and profiling the entire genome of immune cells to understand how transcription and expression of specific genes affects immune cell behavior or leads to dysfunctions in specific cellular pathways that contribute to T cell exhaustion, and is developing and using tools from functional genomics and mass spectrometry to study fundamental properties of the immune system in search of new regulators of anti-tumor immune responses
Matthew H. Spitzer, Ph.D., of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center and Gladstone-UCSF Institute of Genomic Immunology, who is using cutting-edge experimental and computational technologies to explore the role of immune cells circulating outside tumors – rather than those within the tumor microenvironment – in conferring long-term protection against cancer and infection, leading potentially to the identification of therapeutic targets involved in tumor-mediated immune suppression throughout the body.
The Cancer Research Institute named this program in honor of Lloyd J. Old, M.D., the "Father of Modern Tumor Immunology," who served as CRI’s founding scientific and medical director from 1971 to 2011. A mentor to generations of immunologists and tumor immunologists who flourished under his guidance and went on to make significant contributions to the field, Dr. Old embodies the ideals of the STAR program, through which CRI identifies and funds high-impact scientists whose outstanding work has distinguished them as today’s visionaries in cancer immunology.

The following members of CRI’s Scientific Advisory Council leadership comprise the CRI Lloyd J. Old STAR Program Selection Committee:

Carl F. Nathan, M.D., (Committee Chair), R.A. Rees Pritchett Professor of Microbiology and Chair, Department of Microbiology and Immunology, Weill Cornell Medicine
James P. Allison, Ph.D., Regental Professor and Chair of Immunology; Olga and Keith Wiess Distinguished University Chair for Cancer Research; Executive Director of the Immunotherapy Platform; Deputy Director for Applied Research of Genitourinary Cancers; Director of the Parker Institute for Cancer Immunotherapy, University of Texas MD Anderson Cancer Center; and 2018 Nobel Laureate
Glenn Dranoff, M.D., Global Head of Immuno-Oncology, Novartis Institutes for Biomedical Research
Kunle Odunsi, M.D., Ph.D., FRCOG, FACOG, Director, University of Chicago Medicine Comprehensive Cancer Center; Dean of Oncology and Professor of Obstetrics and Gynecology, Division of Biological Sciences, University of Chicago
Ellen Puré, Ph.D., Professor of Pharmacology; Grace Lansing Lambert Professor of Biomedical Science and Chair, University of Pennsylvania School of Veterinary Medicine; Director, Penn Vet Cancer Center; and Member, Abramson Cancer Center, University of Pennsylvania
Robert D. Schreiber, Ph.D., Andrew M. and Jane M. Bursky Distinguished Professor, Pathology and Immunology; Interim Chief, Division of Immunobiology; Director, Center for Human Immunology and Immunotherapy Programs; Co-Leader, Tumor Immunology Program, Siteman Cancer Center, Washington University School of Medicine
E. John Wherry, Ph.D., Chair, Department of Systems Pharmacology & Translational Therapeutics; Richard and Barbara Schiffrin President’s Distinguished Professor; Director, Institute for Immunology; Co-Program Leader, Immunobiology Program, Abramson Cancer Center, and Co-Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania
Jedd D. Wolchok, M.D., Ph.D., Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation; Chief, Immuno-Oncology Service, Human Oncology and Pathogenesis Program; Director, Parker Institute for Cancer Immunotherapy at MSK; and Associate Director, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center.
Applications to the next CRI Lloyd J. Old STAR Program funding round are due January 15, 2023. To learn more about the program, including eligibility and application instructions, go to cancerresearch.org/star.